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Background: Non-receptor protein-tyrosine kinases often
contain at least one Src homology 2 (SH2) domain, a
protein module that binds with high affinity to tyrosine-
phosphorylated peptides. Because SH2 domains would be
predicted to bind with high affinity to proteins phosphory-
lated by the kinase, but not to the unphosphorylated sub-
strate, their presence in tyrosine kinases has been puzzling.
An important role for the SH2 domain of the Abl tyrosine
kinase was suggested by work showing that Abl requires
an intact SH2 domain in order to malignantly transform
cells, and that replacement of the Abl SH2 domain with
heterologous SH2 domains alters the spectrum of proteins
phosphorylated detectably by Abl in vivo.
Results: We have used purified wild-type and mutant
Abl kinases to examine the roles of the Abl's SH2 and
catalytic domains in phosphorylation of p130CAS, a model
substrate that has multiple potential phosphorylation sites.
We find that an SH2 domain is required for efficient
hyperphosphorylation of p130 in vitro. We use chimeric
mutants with heterologous SH2 domains to demonstrate
that the SH2 domain of the oncogenically transforming
adaptor protein Crk, which is the SH2 domain predicted
to bind with highest affinity (of those tested) to potential
phosphorylation sites in p130, is best able to facilitate
hyperphosphorylation. This is the case whether the cat-
alytic domain of the kinase is derived from Abl or from its
distant relative, Src. These studies also reveal a role for
binding of Crk to Abl in mediating phosphorylation by
the kinase. Using purified proteins, we demonstrate that
association with Crk strikingly enhances the ability of Abl
to hyperphosphorylate pl30. There is an excellent cor-
relation between the ability of mutant Crk proteins to
promote hyperphosphorylation of p130 by Abl and their
ability to transform rodent fibroblasts.
Conclusion: Our data suggest that, ultimately, the
substrate specificity of a non-receptor tyrosine kinase is
dependent on the binding specificity of its associated SH2
domain. The SH2 domain binds tightly to a subset of
proteins phosphorylated by the catalytic domain, leading
to processive phosphorylation of those proteins. Substrate
specificity can be broadened by an association between
the kinase and proteins, such as Crk, that contain addi-
tional SH2 domains; this may play a role in malignant
transformation by Crk.
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Background
Protein-tyrosine kinases play a central role in the signal
transduction machinery of complex eukaryotes. Their
importance in regulating cell proliferation is highlighted
by observations that the receptors for many peptide
mitogens have intrinsic tyrosine kinase activity, and that
disregulated tyrosine kinases can often induce malignant
transformation [1]. There are two broad classes of tyro-
sine kinases, the receptor and non-receptor types. The
receptor class contain extracellular ligand-binding and
intracellular catalytic domains, and they are activated by
ligand binding. The non-receptor kinases are entirely
intracellular, and their activity is presumed to be
regulated by association with other proteins.
The substrates phosphorylated by tyrosine kinases have
been the subject of intense research for many years, but
the identification of physiologically relevant substrates has
proven surprisingly difficult. A major reason for this is that
tyrosine-phosphorylated proteins are generally present in
cells at very low levels. Indeed, in cells expressing a trans-
forming tyrosine kinase, or in cells stimulated with the
ligand for a tyrosine kinase growth factor receptor, the
most prominent tyrosine-phosphorylated protein is often
the autophosphorylated kinase itself. This suggests that
the tyrosine kinases do not amplify signals by phosphory-
lating many molecules in a short time, but might instead
signal by selectively phosphorylating only a few proteins.
An important clue to the mechanism of signaling by
tyrosine kinases emerged from studies of the Src homol-
ogy 2 (SH2) domain, a small protein module that is
found in many signaling proteins [2,3]. SH2 domains
bind with high affinity to tyrosine-phosphorylated pep-
tide sequences. Different SH2 domains bind with highest
affinity to different specific peptide sequences, depending
largely on the three amino acids carboxy-terminal to the
phosphorylated tyrosine [4,5]. It has become apparent
that one critical feature of signaling by activated receptor
tyrosine kinases is the binding of SH2-containing pro-
teins from the cytoplasm to tyrosine-phosphorylated sites
on the receptor [6]. Binding to the receptor facilitates
phosphorylation of these cytoplasmic proteins and re-
localizes them so they are in proximity to membrane-
bound substrates.
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Unlike the receptor class, non-receptor tyrosine kinases do
not contain ligand-binding domains, but instead often
contain at least one SH2 domain located amino-terminal
to the catalytic domain. The SH2 region has long been
known to have a modulatory function for the non-recep-
tor tyrosine kinases, but the mechanism of this modulation
is still not entirely clear. In the case of the well-studied Src
kinase, the SH2 domain has both a positive and a negative
role: it helps to hold the non-transforming c-src gene
product in an inactive conformation through interactions
with a carboxy-terminal regulatory phosphotyrosine
within the same Src molecule [7,8], but SH2 mutations
generally decrease the transforming activity of 'activated'
src genes [9-12], suggesting that the domain has a positive
role in phosphorylation by the kinase.
The situation is somewhat different in the case of the Abl
non-receptor tyrosine kinase. Abl was originally isolated
as the product of the transforming gene in Abelson
murine leukemia virus, and the abl gene was subsequently
shown to be fused to sequences from bcr, another chromo-
somal locus, in virtually all cases of human chronic myel-
ogenous leukemia [13-15]. We have previously shown
that an intact SH2 domain is absolutely required for trans-
formation of fibroblasts by an activated abl gene, whereas
no negative role for the SH2 domain is apparent [16,17].
We have also shown that lack of the Abl SH2 domain can
be complemented by its replacement with SH2 domains
from other proteins, and that the spectrum of tyrosine-
phosphorylated proteins in cells expressing these variant
Abl genes varies with the different SH2 domains [17]. We
inferred from these results that an SH2 domain is required
in order to bind to a subset of proteins phosphorylated by
the catalytic domain, thereby allowing repeated 'proces-
sive' phosphorylation of multiple sites on bound proteins,
or else protecting those substrates from dephosphorylation
by tyrosine phosphatases. In the absence of a suitable nat-
ural substrate for Abl, however, it was impossible to test
this model in vitro with purified proteins.
Two groups recently reported [18,19] that Abl can bind
to a class of proteins called SH2-SH3 adaptors, which
consist entirely of SH2 domains together with another
small protein-binding module, the SH3 domain. The
adaptors are thought to function in the coupling of signals
initiated by tyrosine phosphorylation (via SH2 binding)
to downstream effectors (via SH3 binding; reviewed in
[2,3,20]). The binding of one of these adaptors, Crk, was
of particular interest for several reasons. Crk was origi-
nally isolated as the product of an oncogene from avian
sarcoma viruses [21,22], and both the viral forms and the
cellular homolog have the ability to transform cells malig-
nantly when overexpressed [22-24]. Crk-transformed
cells have an increase in the phosphotyrosine content of
several proteins, and the Crk protein is associated with
these phosphoproteins and with tyrosine kinase activity in
lysates [22,25]. Taken together, these results suggested that
endogenous Abl kinase might associate with the Crk
adaptor protein in transformed cells and might be
responsible for the tyrosine phosphorylation observed -
and hence for transformation. It was not known, how-
ever, what effect Crk binding might have on Abl kinase
activity, or how this could be responsible for the apparent
kinase activation seen in Crk-transformed cells.
In this work, we use the major tyrosine-phosphorylated
protein in Crk-transformed cells, pl30CAS (called CAS
for 'Crk-associated substrate') [26], as a model substrate
with which to examine the roles of the SH2 and catalytic
domains in the substrate specificity of the Abl kinase. We
find that an SH2 domain is required for efficient hyper-
phosphorylation of p130. Furthermore, the efficacy of
the SH2 domain in promoting hyperphosphorylation is
correlated with its predicted ability to bind to tyrosine-
phosphorylated sites on the substrate; the most effective
of the SH2 domains tested is that from Crk. Finally, we
show that binding of Crk to Abl serves to stimulate the
ability of Abl to phosphorylate p1 30, consistent with a
model in which Crk transforms cells at least in part by
altering the substrate specificity of Abl and inducing the
hyperphosphorylation of substrates such as p1 30.
Results
An SH2 domain promotes p130 hyperphosphorylatiQn by Abl
We chose to examine the contribution of the SH2 and
catalytic domains to the kinase activity of the Abl non-
receptor tyrosine kinase using p130 as a model substrate;
p130 is the major tyrosine-phosphorylated protein in
fibroblasts that are transformed by the v-crk oncogene,
and phosphorylated p130 binds with high affinity to the
SH2 domain of Crk [26]. We chose this protein as a sub-
strate for several reasons. First, p130 is a good candidate
for a bona fide substrate of c-Abl in vivo, because it is
phosphorylated in cells transformed by Crk, where Abl
and Crk have been shown to be associated with each
other [18,19,26]. The p130 protein is also phosphory-
lated by, and associated with, the Src kinase in Src-trans-
formed cells, suggesting that it might be a good substrate
for a number of different tyrosine kinases [26]. The p130
protein has numerous potential phosphorylation sites,
including nine sites with the sequence Tyr-Asp-X-Pro,
where X is threonine or valine. These sites closely match
the predicted high-affinity binding site for the Crk SH2
domain [4]. It is important that the model substrate has
numerous phosphorylation sites, in order to test whether
the SH2 domain can facilitate processive phosphorylation
of multiple sites on one substrate.
For our kinase assays, we used purified Abl proteins
produced by infection of insect cells with recombinant
baculovirus expressing mutant and wild-type forms of
Abl as fusion proteins with glutathione S-transferase
(GST). Fusion proteins were purified by affinity chro-
matography on glutathione-agarose and cleaved from
GST using thrombin. We also produced p130 as a GST
fusion protein, in this case by transient transfection of
293 cells, and the purified protein was used without
cleaving off the GST. The ability to phosphorylate
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and induced the retarded mobility in SDS polyacryl-
amide gels that is characteristic of proteins highly phos-
phorylated on tyrosine. By contrast, the SH2-deleted
mutant form of Abl phosphorylated p130 to a lower
level and did not efficiently induce the slower-migrat-
ing, presumably hyperphosphorylated species (Fig 1,
lane 1). Under these conditions of relatively high Abl
concentration, a large percentage of the GST-p130 in
the reaction is converted to slower-mobility forms if the
SH2 domain is present, as demonstrated by staining of
the protein bands with Coomassie blue (Fig. lb).
Fig. 1. Phosphorylation of GST-pl30 by purified Abl kinase.
GST-pl 30 was incubated with purified c-Abl protein (lane 2), or
variant proteins in which the SH2 or SH3 domains have been
deleted (lanes 1 and 3, respectively), and kinase assays were per-
formed in vitro in the presence of Iy-32P]ATP. Reaction products
were separated by SDS-PAGE and visualized by (a) auto-
radiography or (b) Coomassie blue staining. Arrows indicate the
position of p130 (lower arrow) and the slower-migrating, hyper-
phosphorylated form of p130 (pp1 30; upper arrow). The posi-
tions and apparent molecular masses of markers (in kD) are
indicated on the left. The prominent band at around 80 kD is
acetylated BSA carrier protein.
GST-p130 in vitro was compared between purified
wild-type c-Abl and derivatives of Abl in which the
SH2 or SH3 domains have been deleted by mutagenesis
in vitro. As shown in Figure la, both c-Abl itself and the
SH3-deleted kinase were able to phosphorylate p130
Retarded mobility on SDS gels is commonly observed
when proteins are phosphorylated, and we assume that
the slower-migrating forms are multiply phosphorylated
for several reasons. In previously published work [26] and
in our experiments, the most slowly migrating p13 0
species react more intensely with anti-phosphotyrosine
antibodies than with antibodies against p130 (or GST,
in the case of GST-pl30), relative to the more rapidly
migrating forms. Furthermore, when the stoichiometry
of phosphorylation was calculated using labeled ATP,
more than 1 mole of phosphate per p130 molecule was
detected in the slower-migrating forms (data not shown).
The complex 'ladder' of intermediate apparent molecular
weights also suggests multiple phosphorylation sites, but
makes precise determination of the stoichiometry of
phosphorylation of any component band difficult.
Finally, in pulse-chase experiments using labeled ATP,
radioactivity could be chased from the more rapidly
migrating form to the more slowly migrating forms after
Fig. 2. Structure of chimeric Abl kinases,
drawn to scale. Positions of the SH3,
SH2 and catalytic domains are indi-
cated, as is the proline-rich site in the
carboxy-terminus (Pro), which binds to
the Crk SH3 domain. For mutants con-
taining heterologous SH2 domains, the
origin of the SH2 domain is indicated
(PIK denotes PI 3-kinase p85 subunit).
The name of each construct is shown on
the left of the figure. GST is fused to the
amino terminus of all kinases used for
the experiment shown in Fig. 3, and is
not shown in this figure.
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incubation with an excess of unlabeled ATP, demonstra-
ting that the slower-migrating forms are more highly
phosphorylated (data not shown).
The three Abl variants had equal activity toward mono-
valent substrates, such as angiotensin, or high concentra-
tions of non-specific co-polymer substrate poly(Glu-Tyr),
when tested under similar kinase conditions ([17] and
data not shown). The mutant lacking the SH2 domain is
therefore not impaired in kinase activity in general, but it
is impaired in the ability to hyperphosphorylate low con-
centrations of the multivalent substrate p1 30. These data
are entirely consistent with a model in which the SH2
domain does not affect kinase activity directly, but
instead has an indirect effect in promoting processive
phosphorylation by binding to phosphorylated product.
Because we used purified proteins, the tyrosine phos-
phatase activity in the reactions is likely to be low relative
to the kinase activity, so the results are inconsistent with
a model in which SH2 domains enhance phosphoryla-
tion by merely protecting the product from dephos-
phorylation. Similar results are obtained if the tyrosine
phosphatase inhibitor sodium orthovanadate is present in
the reaction mix (data not shown).
of whether they contained the Abl or the Src catalytic
domain. For each series, the mutant with the PI 3-kinase
SH2 domain was the poorest at p130 hyperphosphoryla-
tion, whereas the mutants with the Abl, Src and GAP
SH2 domains were intermediate in activity. The mutant
containing only the Abl SH2 and catalytic domains was
surprisingly weak in p130 hyperphosphorylating activity
compared with other mutants in these conditions, but as
shown in Figure 1 and on longer exposures of this gel, the
Abl SH2 increased p130 hyperphosphorylation relative to
that obtained with the mutant lacking an SH2 domain.
The mutant kinases were normalized for their ability to
phosphorylate the nonspecific poly(Glu-Tyr) co-polymer
The Crk SH2 domain specifically directs
hyperphosphorylation of p130
We next examined the relative contributions of the SH2
and catalytic domains to substrate specificity, as assayed by
hyperphosphorylation of p130. For these experiments,
we used the panel of mutant Abl kinases shown in
Figure 2. The mutants ASH3, GG, GS, GP and GC are
variants of Abl in which the SH2 domain is derived from
Abl, GAP (the Ras GTPase activator protein; amino-
terminal SH2 domain), Src, phosphatidylinositol (PI)
3-kinase p85 subunit (carboxy-terminal SH2 domain) or
Crk, respectively. To test the effect of a catalytic domain
other than that of Abl, the 'GSC' series of mutants was
constructed containing the same series of SH2 domains
but with the Abl catalytic domain replaced with that of
the Src tyrosine kinase. This collection of mutant pro-
teins allows the controlled analysis of contributions by
the SH2 and catalytic domains, because all mutants are in
the same 'framework' provided by the amino- and car-
boxy-terminal sequences derived from Abl. All of these
kinases have the ability to transform NIH 3T3 cells to
some extent [17], demonstrating that the modular SH2
and catalytic domains can function in the context of the
Abl backbone (the SH3 domain is deleted in all these
mutants; this is required in the case of Abl in order for
the kinase to have transforming activity, but it has no
apparent effect on kinase activity in vitro).
The mutants shown in Figure 2, including a mutant that
contains the SH3 domain but lacks any SH2 domain
(ASH2), were expressed as GST fusion proteins, purified
by affinity chromatography, eluted and assayed for their
ability to phosphorylate GST-p130. As shown in
Figure 3a, the kinases containing the Crk SH2 domain
were best able to hyperphosphorylate p130, irrespective
Fig. 3. SH2-dependence of phosphorylation of p130 by chimeric
Abl mutants. The kinases shown in Fig. 2 were purified and used
to phosphorylate purified (a) GST-p1 30 CAs or (b) poly(Glu-Tyr).
In (c) no exogenous substrate was included. Products of kinase
assays in vitro were separated by SDS-PAGE and visualized by
autoradiography. The arrow in (c) indicates the position of
autophosphorylated GST-Abl kinase. The positions and apparent
molecular weights (in kD) of markers are indicated on the left.
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substrate (Fig. 3b), so again there was no global effect of
SH2 domain substitution on kinase activity. The mutants
that had Src catalytic domains were much more active
than those with the Abl catalytic domain (approximately
15-20-fold higher specific activity) in phosphorylating
poly(Glu-Tyr), whereas there was little difference in their
relative ability to phosphorylate p130 (for example, com-
pare lanes 7 and 12, Figs 3a and 3b). This is consistent
with the predicted specificity of the Src and Abl catalytic
domains, as determined recently by Cantley and col-
leagues [27]. They showed that Abl preferentially phos-
phorylates sites containing small hydrophobic residues,
whereas Src has a strong preference for acidic residues
both amino- and carboxy-terminal to the phosphorylated
tyrosine. The random glutamic acid-tyrosine co-polymer
substrate is highly acidic and more nearly conforms to
the preferences of the Src catalytic domain. Figure 3c
shows the autophosphorylating activity of the various
mutant kinases in the same conditions as those used in
Figure 3a (except for the lack of p130 substrate), demon-
strating that autophosphorylation occurred at roughly the
same level for all the mutants and was insignificant com-
pared to phosphorylation of exogenous p130 substrate.
Similar results were obtained if Abl was first cleaved from
GST using thrombin (data not shown).
The results described above are again consistent with a
model in which processive phosphorylation depends on
binding of an early phosphorylated tyrosine to the SH2
domain. The Crk SH2 domain is predicted to have a
Fig. 4. Binding of Crk affects phosphorylation of p130 by Abl
kinase. Purified, dephosphorylated c-Abl kinase was used to
phosphorylate GST-p130 in vitro. Reaction products were sepa-
rated by SDS-PAGE and visualized by (a) autoradiography or (b)
Coomassie blue staining. The purified GST-Crk proteins indi-
cated above each lane were pre-incubated with the c-Abl kinase
before the kinase reaction. Arrows indicate (from the bottom of
the figure) the positions of GST-Crk-1 protein, GST-Crk-2 pro-
tein, GST-p130, and hyperphosphorylated GST-p130 (pp130).
Positions and apparent molecular masses (in kD) of markers are
indicated on the left.
very high affinity for many of the potential tyrosine
phosphorylation sites in p130. Cantley's group [4,5] has
shown that aspartic acid in the +1 position and
(especially) proline in the +3 position are strongly
selected by the Crk SH2 domain; nine of the potential
p130 phosphorylation sites contain these residues. The
Src and Abl SH2 domains are predicted to have moder-
ately high affinity for several of the potential phosphory-
lation sites (although the Abl SH2 domain also selects
proline at the +3 position, the selection is not as strong
as for the Crk SH2 domain and there is no selection for
aspartate at +1). The GAP SH2 domain's binding pref-
erence has not yet been published, but by sequence
comparison it is predicted to be in the same general class
as Crk, Src and Abl. The SH2 domain that is predicted
to bind most poorly is that from PI 3-kinase, which is
highly selective for a hydrophobic residue at +1 and
especially for methionine at +3. There are no tyrosines
in p130 that conform to this consensus.
The origin of the catalytic domain has little influence on
the hyperphosphorylation of p1 30; mutants with catalytic
domains from Src or Abl are roughly equal in their ability
to phosphorylate p130. There certainly is specificity in
catalytic domains, as shown by Cantley's group [27] and
by the preferential phosphorylation of poly(Glu-Tyr) by
the kinases containing the Src catalytic domain; but in
this study, with moderately low concentrations of a physi-
ological substrate, the SH2 domain is critical in determin-
ing whether or not processive phosphorylation will occur.
Effect of Crk binding to Abl kinase
The results outlined above demonstrate that within a
single molecule (in cis), the Crk SH2 domain is much
more effective than that of Abl in promoting the hyper-
phosphorylation of p1 30. We were therefore interested in
whether binding of Crk protein to Abl in trans could give
the same effect. Because Crk binds via its SH3 domain to
Abl [18,19], its SH2 domain is free to bind to proteins
phosphorylated by the catalytic domain, and might there-
fore be expected to facilitate processive phosphorylation.
Crk is found in two forms generated by alternate splicing,
Crk-1 and Crk-2, which have one or two SH3 domains,
respectively [24]. In normal cells, the Crk-2 form pre-
dominates [23,24,28]. High levels of overexpression of
the Crk-1 form can transform rodent fibroblasts, whereas
the Crk-2 form is less active in this assay [23,24]. We find
that the Crk-2 form consistently causes morphological
alteration and increased saturation density when over-
expressed in NIH 3T3 cells, but the morphology of cells
is less dramatically altered than in cells expressing the
Crk-1 form (our unpublished observations). Mutagenesis
studies have shown that both an intact SH2 domain and
an amino-terminal SH3 domain are required for transfor-
mation of chicken embryo fibroblasts by v-crk [29], for
coupling of growth-factor receptors to Ras by micro-
injected Crk-1 and Crk-2 in PC12 cells [30], and for
morphological alteration of NIH 3T3 cells by Crk-1 and
Crk-2 (BJ.M., unpublished observations).
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Feller and Hanafusa [18] have proposed that tyrosine
phosphorylation of Crk-2 is responsible for its weaker
transforming activity, because intramolecular SH2-phos-
photyrosine interactions would make the SH2 domain
unavailable for interaction with other proteins in trans.
We mutated the major site of tyrosine phosphorylation of
Crk-2 (tyrosine 222 in the chicken c-Crk used here) to
phenylalanine, to assess the effect on p130 phosphory-
lation. As seen in Figure 4, unlike wild-type Crk-2, the
Crk-2F2 22 mutant is not efficiently tyrosine phosphory-
lated, and it is now as active as Crk-1 as a p130 processiv-
ity factor (Fig. 4, lane 5; compare with lanes 2 and 4).
Consistent with this, when expressed in 3T3 cells by
retroviral infection, the Crk-2F2 2 2 mutant induces a
transformed morphology similar to that of cells express-
ing Crk-1 and unlike the more subtle alteration induced
by Crk-2 (our unpublished observations).
For kinase assays in vitro, purified Abl kinase was
incubated with an excess of bacterially produced
GST-Crk-1 or GST-Crk-2 fusion protein, and then
GST-pl130 substrate was added in a reaction mixture
containing Mg2 + and labeled ATP. As shown in Figure 4,
under these conditions Abl cannot hyperphosphorylate
p130 in the absence of added Crk protein (lane 1).
However, if either Crk-1 or Crk-2 protein is prebound
to Abl, p130 is efficiently hyperphosphorylated, as indi-
cated by the appearance of a slower-migrating p130 band
(Fig. 4, lanes 2 and 4). This demonstrates that the Crk
SH2 domain in trans can alter the activity of Abl towards
p130. In contrast to its effect on p130 hyperphosphoryla-
tion, Crk binding had no effect on the activity of Abl
toward the monovalent substrate, angiotensin (Table 1).
The ability of Crk peptides to facilitate processive
phosphorylation correlated with their ability to induce
transformation. The Crk-1 form is more active than the
Crk-2 form in stimulating p130 hyperphosphorylation
(Fig. 4, compare lanes 2 and 4), correlating with its
stronger transforming activity. As expected, if the SH3
domain of Crk-1 is mutated by a single amino-acid
change that eliminates binding to Abl, the mutant Crk
protein is unable to act as a processivity factor (Fig. 4,
lane 3). Furthermore, a Crk-2 protein in which the SH2
domain carries a mutation in its phosphotyrosine-binding
site is much weaker in facilitating processive phosphory-
lation (Fig. 4, lane 6).
From the results shown in Figure 4, it is apparent that
Crk-2 protein is highly phosphorylated by Abl, whereas
Crk-1 is phosphorylated only at a low level (Fig. 4, lanes
2 and 4). This is also the case in vivo, where Crk-2 (but
not Crk-1) is tyrosine-phosphorylated when over-
expressed ([18] and BJ.M., unpublished observations).
We next examined the concentration of Crk-1 protein
necessary to induce hyperphosphorylation of p130 by
Abl. We tested both c-Abl and an SH3-deleted form of
Abl, which unlike c-Abl is highly transforming when
expressed in 3T3 cells. The reason we wished to compare
the two forms is that it is possible that the SH3 domain
of Abl might itself compete with the Crk SH3 domain
for binding to the proline-rich site in the Abl carboxyl
terminus. If this were the case, then higher 'concentra-
tions of Crk would be required to bind to the wild-type
c-Abl than to the SH3-deleted form. As shown in Figure
5, similar concentrations of Crk protein are required to
promote hyperphosphorylation of p130 by c-Abl (left)
Fig. 5. Concentration-dependence of the ability of GST-Crk to
facilitate hyperphosphorylation of p130 by c-Abl and by an Abl
SH3 domain deletion mutant. GST-Crk-1 protein was preincu-
bated with purified, dephosphorylated c-Abl kinase (left) or the
ASH3 deletion mutant kinase (right). Kinase assays were per-
formed in vitro using GST-p130 as substrate, and 32P-labeled
reaction products were separated by SDS-PAGE and visualized
by autoradiography. For each set of reactions, the concentration
of GST-Crk was decreased three-fold in adjacent lanes. Arrows
indicate the positions (from bottom of figure) of GST-Crk-1 pro-
tein, GST-p130 and hyperphosphorylated GST-p130 (pp130).
Approximate initial concentrations of GST-Crk-1 protein in each
lane were as follows: lane 1, 0.25 mg ml-1; lane 2, 83 pRg ml-1;
lane 3, 28 jig ml-1; lane 4, 9.3 Itg ml-1; lane 5, 3.1 g ml-];
lane 6, 1.0 g ml-1; lane 7, none. Positions and apparent
molecular masses (in kD) of markers are indicated on the left.
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or the transforming, SH3-deleted form of Abl (right),
suggesting that the Abl SH3 domain does not block Crk
binding. For both forms of Abl, half-maximal stimulation
of hyperphosphorylation is seen at concentrations of
Crk protein of between 10- 6 and 10- 7 M, suggesting that
there is a high-affinity interaction between Crk and Abl
that could occur under physiological conditions.
Discussion
The work described here provides a mechanistic explana-
tion for the role of the SH2 domain in non-receptor
tyrosine kinases. Although it has long been recognized
that the SH2 domain plays a positive role in the trans-
forming activity of activated alleles of the src and abl
kinase-encoding genes, and that it can affect the phos-
phorylation of particular substrates in vivo, the mecha-
nism was obscure. We have shown here that an SH2
domain is required for the efficient processive phospho-
rylation of a multivalent substrate, and that the efficacy of
an SH2 domain correlates with its predicted ability to
bind tightly to phosphorylated sites on the substrate pro-
tein. We have also shown that the Crk adaptor protein
can bind to Abl and donate its SH2 domain in trans,
serving as a processivity factor for the kinase.
Our results suggest that processive phosphorylation is
triggered by binding of the SH2 domain of the kinase (or
of an associated protein such as Crk) to a tyrosine-
phosphorylated site on a substrate protein. Thus, both
the catalytic and SH2 domains contribute to determining
which proteins become highly phosphorylated. The SH2
domain cannot bind to a substrate unless it is first phos-
phorylated by the catalytic domain, but processive phos-
phorylation will not occur unless the SH2 domain can
bind tightly to the phosphorylated site. Once bound, the
extremely high local concentration of the bound sub-
strate drives phosphorylation of all sites that are sterically
accessible to the catalytic domain. It is interesting that
Cantley's group [27] has found that the substrate speci-
ficity of the catalytic domains of various non-receptor
tyrosine kinases correlates quite well with the specificity
of their associated SH2 domains, suggesting that the two
domains co-evolved in order to achieve processive
phosphorylation of substrates.
Although few biologically relevant substrates are known
for the non-receptor tyrosine kinases, the finding that in
several cases, perhaps best illustrated by the T-cell recep-
tor complex [31], many sites with similar sequence con-
texts are present on the same substrate molecule suggests
a functional role in vivo for the type of processive phos-
phorylation described here. Furthermore, Wang's group
has reported [32] that c-Abl can phosphorylate the
carboxy-terminal domain of RNA polymerase II to
very high stoichiometry. We suggest that processive
phosphorylation is biologically important, providing a
means by which to generate coordinate 'all-or-nothing'
phosphorylation of many sites on a substrate protein
even at low concentrations of both substrate and kinase.
Certainly, the observation that the Abl kinase requires an
SH2 domain in order to be able to transform cells [17]
suggests that processive phosphorylation of proteins
might have profound physiological consequences.
It is of particular interest that substrate specificity can be
altered by the binding of heterologous SH2 domains in
separate molecules (in trans). This would allow a single
kinase to be directed to different substrates, depending
on the local availability of 'processivity factors' such as
Crk. Proteins other than Crk are also likely to function
in such a role. For example, the Grb2 adaptor binds to
the Abl carboxyl terminus [18,19] and can facilitate pro-
cessive phosphorylation (data not shown); another SH2-
containing protein, 3BP2, has also been shown to bind to
the Abl SH3 domain [33-35]. Abl may actually be associ-
ated in vivo with a number of different 'prosthetic' SH2
domains, allowing it to target a wide range of potential
substrates. Our results also suggest a straightforward and
rational way to redirect the substrate specificities of the
non-receptor kinases by appending selected SH2
domains in cis or in trans.
The binding of Crk to Abl raises the possibility that Crk
binding may be important for the biological activity of
Abl, or conversely that Abl binding may be critical for
transformation by Crk. Although not required for the
transformation of fibroblasts, the carboxyl terminus of
Abl is required for the transformation of lymphoid cells
[36], suggesting that Crk binding could b-eimportant for
targeting lymphoid-specific substrates. Although it is not
yet known whether p130 is a natural target of Abl in
vivo, transfection of 293 cells with Abl greatly increases
tyrosine phosphorylation of GST-p130, and this
depends on the presence of an intact SH2 domain in Abl
(data not shown).
It is likely that endogenous c-Abl is at least partly re-
sponsible for the increase in tyrosine phosphorylation of
cellular proteins (including p1 30) that is seen in cells
transformed by overexpression of Crk, given that the
Abl-Crk complex has been shown to exist in vivo
[18,19], and we show here that the complex can very
efficiently phosphorylate p1 30 in vitro. A role for Abl in
transformation by Crk is also suggested by the correlation
between the transforming activity of Crk mutants and
their ability to promote p130 hyperphosphorylation by
Abl. Consistent with this, co-transfection of c-Abl with
Crk-1 or Crk-2 induces hyperphosphorylation of
GST-pl30 in 293 cells, as compared to parallel transfec-
tions lacking either Crk or Abl; in addition, co-transfec-
tion of Crk can rescue the inability of Abl mutants
lacking an SH2 domain to phosphorylate GST-pl130
(our unpublished observations).
Finally, these results suggest a novel role for the SH2-SH3
adaptor proteins: they may act as processivity factors for
Abl and perhaps other kinases. Current models of adaptor
protein function are based on the Grb2/Sem5 paradigm,
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Fig. 6. Model for the role of SH2 domains in the phosphorylation of substrate proteins.
derived largely from genetic studies in Caenhorabditis
elegans and Drosophila melanogaster [37-39]. These studies,
together with biochemical analyses, suggested that Grb2
serves to couple membrane events to downstream effec-
tors, specifically by binding to autophosphorylated
growth factor receptors through its SH2 domain and to
the Ras activator, Sos, through its SH3 domains [20].
Our studies suggest that we should consider a more gen-
eral role for the adaptors in modulating the binding
activity of proteins with which they associate.
Conclusion
SH2 domains are found in most non-receptor tyrosine
kinases. We propose that the SH2 domain functions in
these kinases to facilitate the processive phosphorylation
of substrate proteins that have multiple potential phos-
phorylation sites. Our model is outlined in Figure 6.
Once the catalytic domain has phosphorylated a site on a
substrate protein, there are two possible outcomes. If the
tyrosine-phosphorylated site cannot bind an SH2
domain on the kinase, either because the site has low
affinity for the SH2 domain or because the SH2 domain
has been deleted or mutated, then the substrate will be
released. Because of the high levels of tyrosine
phosphatase activity in normal cells, the substrate is
likely to be rapidly dephosphorylated. If, on the other
hand, the phosphorylated site can bind with high affinity
to a kinase-associated SH2 domain, many other sites on
the substrate will be subsequently phosphorylated as a
result of their proximity to the catalytic domain.
Although most non-receptor tyrosine kinases contain an
SH2 domain in cis (within the same molecule as the cat-
alytic domain), we have shown that the Abl kinase can
also acquire an additional SH2 - that of the Crk adap-
tor protein - in trans. The bound adaptor serves as a
processivity factor, by broadening the range of phos-
phorylated sites that can tightly bind to the kinase, and
serves to initiate processive phosphorylation. This pro-
posed mechanism is likely to be involved in the normal
function of the non-receptor kinases, and in their abnor-
mal function in cells malignantly transformed by mutant
kinases or by the crk oncogene.
Materials and methods
DNA constructs
The construction of baculovirus vectors expressing the murine
type IV c-abl product fused to GST, and various mutants
derived from the wild-type c-abl, has been described previously
[17]. The.mutants termed E, F and G in our previous publica-
tion [17] are termed ASH2, c-Abl and ASH3, respectively, in
this study. For expression of GST-Abl fusion proteins in mam-
malian cells by transient transfection, the vector pEBG was
used; pEBG is derived from pEF-BOS, an expression vector
driven by the human elongation factor 1-ao promoter [40]. The
BstXI-NotI stuffer fragment of pEF-BOS was replaced with a
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polylinker containing a BamHI site. The polymerase chain
reaction (PCR) was used to generate a fragment containing the
GST-coding region of pGEX-2T [41], with a 5' BglI site and
eukaryotic ribosome binding site and the 3' BamHI site of
pGEX-2T, which was then inserted into the BamHI site to
generate pEBG. Coding regions of various abl mutants were
cloned into the BamHI and Notd sites of pEBG as described
previously for the baculovirus expression vectors [17], resulting
in the BamHI site of GST being followed in-frame by the
codon for the position 2 glycine of Abl.
The coding region for the short form of rat p13 0CAS [26] was
also cloned into pEBG. PCR was used to synthesize a DNA
fragment corresponding to the entire coding region of p130.
The 5' primer contained a BamHI site followed by the
nucleotides GGCACC (encoding glycine and threonine) fol-
lowed by the initiation codon and 16 additional homologous
nucleotides. The 3' primer was homologous to nucleotides
2932-2955 of the published sequence, which contain the ter-
mination codon, and included a terminal Notd site. The frag-
ment was amplified using fu DNA polymerase (Stratagene) to
reduce polymerase errors, digested with BamHI and NotI, and
cloned into pEBG. Two independent PCR clones were char-
acterized; both behaved identically, and their termini had the
expected DNA sequence.
The GST-Crk fusion proteins will be described more fully
elsewhere. Briefly, PCR was used to amplify full-length
chicken c-crk cDNA (Crk-2) [28], or a fragment of the chicken
gene corresponding to the human Crk- 1 form. Amplified frag-
ments containing 5' BamHI and 3' Notd sites were cloned into
a modified form of pGEX-2T (termed pGEX-2N) containing
a Notl site 3' to the BamHI site. Mutants with single amino-
acid changes in the SH3, SH2 or tyrosine phosphorylation sites
were generated by PCR using mutant oligonucleotides.
Mutant Crk-1K17O is a Crk-1 protein with lysine instead of
tryptophan at position 170 (which corresponds to the invariant
tryptophan found in all SH3 domains). Mutant Crk-2K 38 is a
Crk-2 protein with lysine instead of arginine at position 38
(corresponding to the invariant arginine in the phosphate-
binding site of all SH2 domains). Crk-2F22 2 is a Crk-2 protein
with a phenylalanine instead of tyrosine 222, the major site of
tyrosine phosphorylation [181.
Protein production and purification
The purification of recombinant GST-Abl proteins from bac-
ulovirus-infected Sf9 insect cells and cleavage from GST with
thrombin has been described previously [17]. For some experin-
ments (Fig. 4, Fig. 5 and Table 1), the purified Abl proteins
were dephosphorylated with recombinant tyrosine phosphatase
produced in E. coli, because c-Abl protein is not normally
phosphorylated on tyrosine in vivo [42,43], but when produced
in insect cells it has significant tyrosine phosphorylation ([42]
and data not shown). A plasmid encoding GST-PTP-1B [44]
was kindly provided by B. Neel. Bacteria expressing the phos-
phatase were inoculated 1:20 from overnight cultures into pre-
warmed LB medium, grown for 2 h at 37 °C, then induced
with 0.1 mM IPTG. After growing for 3 h, cells were har-
vested and lysed by sonication in 0.1 culture volume of PLB
buffer (20 mM Tris, pH 7.4, 150 mM NaCI, 10 mM
Na2EDTA, 10 mM DTT, 10 % glycerol, 1 % Triton X-100,
1 mM PMSF, 20 ,ug ml- 1 aprotinin). Lysates were cleared at
16 000 x g for 5 min and GST-PTP-1B was bound to glu-
tathione-agarose beads (Molecular Probes). Beads were washed
four times with PRB buffer (20 mM Tris, pH 7.4, 150 mM
NaCl, 2 mM Na2 EDTA, 2 mM DTT, 10% glycerol, 0.1 %
Triton X-100, 1 mM PMSF, 20 pLg ml-' aprotinin), then puri-
fied, thrombin-cleaved Abl protein was added to beads in PRB
and incubated with' rotation at room temperature for 30 min.
The supernatant was then passed over a column with immobi-
lized phosphotyrosine-specific monoclonal antibody PY20 [45]
to remove residual tyrosine-phosphorylated protein. The
resulting Abl protein contained no detectable phosphotyrosine
by immunoblotting with anti-phosphotyrosine antibodies.
GST-p130 and the GST-Abl variants used in the experiment
shown Figure 3 were produced by transient transfection of 293
cells with EBG-derived plasmids. Cells were transfected with
4 Rg of plasmid DNA per 10 cm dish by calcium phosphate
co-precipitation, essentially as described [46]. Cells were har-
vested 2 days post-transfection in 1 ml TXB buffer (10 mM
Tris, pH 7.4, 150 mM NaCl, 5 mM Na2EDTA, 10 % glycerol,
1 % Triton X-100, 1 mM DTT, 1 mM PMSF, 20 pg ml-1
aprotinin), and lysates were cleared by centrifugation and incu-
bated with glutathione-agarose beads at 4 C. Beads were
washed with TNGT buffer (10 mM Tris, pH 7.4, 150 mM
NaCl, 10 % glycerol, 0.1 % Triton X-100) and eluted in a
small volume of TNGT supplemented with 20 mM reduced
glutathione (pH 7.4) and 1 mM DTT. Acetylated BSA was
added to reach a final concentration of 0.1 mg ml-' and puri-
fied proteins were stored at -70 °C. GST-Crk fusion proteins
were produced in E. coli and purified as described [41].
Proteins were quantitated by Bradford assay (BioRad) using
human y-globulin as a standard, and stored in PBS containing
10 % glycerol.
Kinase assays
Kinase reactions were performed in a buffer containing 50 mM
Hepes, pH 7.4, 10 mM MgCI2, 0.1 mg ml-' acetylated BSA,
100 p.M ATP and 5-10 p.Ci per reaction [y- 32P]ATP at 30 °C
for 5-10 min. GST-p130 substrate was used at an estimated
final concentration of 10-25 g ml-1; poly(Glu-Tyr) (4:1;
Sigma P-0275) was used at 0.5 mg ml-1; and (Val5 )angiotensin
II (Sigma A-2900) was used at 1 mg ml-'. In experiments using
dephosphorylated Abl proteins, 1 mM Na3VO 4 was included
to inhibit any contaminating phosphatase. For analysis of reac-
tion products by gel electrophoresis, 20 p.1 reactions were ter-
minated by adding 5 p.1 five-fold concentrated Laemmli sample
buffer, boiled for 3 min, and separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) on 8.5 % or 12 % polyacryl-
amide gels. Gels were fixed for 3 x 20 min in 10 % acetic acid,
10 % methanol (a trace of Coomassie brilliant blue was present
in the first fix to stain proteins), dried and exposed for autora-
diography at room temperature. Radioactive phosphate incor-
porated into angiotensin was quantitated by phosphocellulose
paper binding as previously described [17]. Radioactive phos-
phate incorporated into poly(Glu-Tyr) was quantified by
cutting gel bands and 'Cerenkov counting in a liquid scin-
tillation counter. Within an experiment, the different Abl-
derived kinases were normalized for equal activity toward
poly(Glu-Tyr) or (Val5 )angiotensin II. In all cases, Abl concen-
trations were low relative to those of p130 substrate, but were
not precisely calculated; in the experiments shown in Figure 1,
-25 ng purified kinase was used per reaction, whereas in the
experiments shown in Figures 4 and 5, -2.5 ng was used.
For experiments involving Crk binding, purified GST-Crk pro-
teins were added to purified, dephosphorylated Abl along with
p130 substrate in a total volume of 8 p.l, and incubated on ice for
20 min; we then added a cocktail containing reaction buffer
components (12 p.l total) and incubated at 30 °C for 5 min. For
the experiment shown in Figure 4, initial (binding) and final
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(reaction) GST-Crk concentrations were approximately 5 and
2 F.M, respectively. For the experiment shown in Figure 5, the
highest GST-Crk concentration (lane 1) was the same as in
Figure 4 and was decreased serially three-fold (giving initial and
reaction concentrations of approximately 20 and 8 nM, respec-
tively, for the lowest concentration shown, in lane 6).
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